Руководство ВОЗ по информированию и гармонизации процессов обеспечения готовности и реагирования при пандемии на национальном и международном уровне
Руководс...во ВОЗ "Управление рисками, связанными с пандемией гриппа", содержит обновленную информацию и заменяет "Руководство ВОЗ по обеспечению готовности к пандемии гриппа и ответным мерам", которое было опубликовано в 2009 г.
more
Рекомендации ВОЗ по оказанию дородовой помощи для формирования положительного опыта беременности
Health and Human Rights Journal
December 2016 / Volume 18 / Number 2 / Papers, 171-182
Session V: Regulatory & quality assurance aspects
Update on prequalification of ARVs and regional harmonisation of medicine registration
Deusdedit K. Mubangizi
Group Lead, Inspections, WHO-PQT E-mail: mubangizid@who.int
Acknowledgements:
• Matthias Stahl
• Milan Smid
• Antony Fake
...• Jacqueline Sawyer
• Iveta Streipa
D-Building – UNAIDS
Kofi A. Annan Meeting Room
Wednesday, 9 March 2016 11:15 – 11:30
more
The dual epidemic of TB and Diabetes
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
Improving access to assistive technology for everyone, everywhere.
The first WHO Priority Assistive Products List was launched in May 2016. The List includes hearing aids, wheelchairs, communication aids, spectacles, artificial limbs, pill organizers, memory aids and other essential items for many... older people and people with disabilities to be able to live a healthy, productive and dignified life.
Available in English, Arabic, Chinese, French, Russian, Spanish
more
BioMed Central DOI 10.1186/s12963-016-0096-y
This guide provides national stakeholders and advocates with information and guidance to update the national essential medicines list to include a new commodity, a new indication, or a new formulation based on the available evidence and based on country need and disease burden. While the actors, tim...eline, and process may vary from country to country, this guide presents the broad steps involved in revising an EML for any health commodity. Additional resources and a glossary are included to provide supplemental information and to clarify key terms.
more
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle...d. Section 4 highlights key achievements and enabling factors for the response to artemisinin resistance, whilst Section 5 provides a more detailed discussion of major issues to be addressed.
more